Sugi Predict

Sugi Predict / Compounds / SCHEMBL298676

SCHEMBL298676

SCHEMBL298676

CC(C)(C)[Si](C)(C)Oc1ccc2c(c1)c(I)nn2C1CCCCO1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 6/20 0.36
▸ CYP4A11 Q02928 6/20 0.36
▸ CA12 O43570 4/20 0.36
▸ CA1 P00915 4/20 0.36
▸ CA9 Q16790 4/20 0.36
▸ RXRA P19793 1/20 0.34
▸ RXRB P28702 1/20 0.34
▸ RXRG P48443 1/20 0.34
▸ PREP P48147 2/20 0.33
▸ GAA P10253 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ RET P07949 2/20 0.31
▸ ATR Q13535 2/20 0.31
▸ DRD1 P21728 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16100337 1.00 CYP4F2 (0.36) CYP4F2CYP4A11CA12CA1CA9
SCHEMBL16100099 0.85 RXRA (0.33) CYP4F2CYP4A11CA12CA1CA9
SCHEMBL16100100 0.85 RXRA (0.33) CYP4F2CYP4A11CA12CA1CA9
SCHEMBL27031973 0.85 CYP4F2 (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29925776 0.85 CYP4F2 (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL16100137 0.85 RXRA (0.37) CYP4F2CYP4A11CA12CA1CA9
SCHEMBL16100139 0.85 RXRA (0.37) CYP4F2CYP4A11CA12CA1CA9
SCHEMBL26741104 0.85 RXRA (0.35) CYP4F2CYP4A11CA12CA1CA9
SCHEMBL29925580 0.85 RXRA (0.35) CYP4F2CYP4A11CA12CA1CA9
SCHEMBL16099889 0.83 RXRA (0.38) CYP4F2CYP4A11CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors ONCODESIGN PRECISION MEDICINE (FR) 2026-02-10 — — US disclosed
EP-4146658-B1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PREC MEDICINE OPM (FR) 2025-10-29 — — EP disclosed
US-12441707-B2 Indazole compounds TYRA BIOSCIENCES, INC. (US) 2025-10-14 — — US disclosed
US-20250248998-A1 LRRK2 Inhibitors Brenig Therapeutics, Inc. 2025-08-07 — — US disclosed
CN-120004858-A Fibroblast growth factor receptor inhibitor, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2025-05-16 — — CN disclosed
WO-2025061029-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2025-03-27 — — WO disclosed
EP-4504722-A2 LRRK2 INHIBITORS Brenig Therapeutics, Inc. (US) 2025-02-12 — — EP disclosed
CN-119306723-A Indazole FGFR2/3 selective inhibitor, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2025-01-14 — — CN disclosed
CN-118684664-A Benzopyrazoles 海南先声再明医药股份有限公司 2024-09-24 — — CN disclosed
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS SERVIER LAB (FR) 2024-07-25 — — US disclosed
WO-2014153235-A2 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-09-25 — — WO disclosed
US-8530665-B2 Crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol ELI LILLY AND COMPANY (US) 2013-09-10 — — US disclosed
EP-2625175-A1 CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3, 5 -DICHLOROPYRIDIN-4 -YL) ETHOXY) - 1H - INDAZOL - 3 - YL) VINYL) -1 H- PYRAZOL- 1 -YL) ETHANOL AND ITS USE AS FGFR INHIBITOR Eli Lilly and Company (US) 2013-08-14 — — EP disclosed
EP-2427449-B1 VINYL INDAZOLYL COMPOUNDS LILLY CO ELI (US) 2013-04-03 — — EP disclosed
US-8268869-B2 Vinyl indazolyl compounds ELI LILLY AND COMPANY (US) 2012-09-18 — — US disclosed
WO-2012047699-A1 CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3, 5 -DICHLOROPYRIDIN-4 -YL) ETHOXY) - 1H - INDAZOL - 3 - YL) VINYL) -1 H- PYRAZOL- 1 -YL) ETHANOL AND ITS USE AS FGFR INHIBITOR ELI LILLY AND COMPANY (US) 2012-04-12 — — WO disclosed
US-20120083511-A1 CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL ELI LILLY AND COMPANY (US) 2012-04-05 — — US disclosed
EP-2427449-A1 VINYL INDAZOLYL COMPOUNDS Eli Lilly and Company (US) 2012-03-14 — — EP disclosed
WO-2010129509-A1 VINYL INDAZOLYL COMPOUNDS ELI LILLY AND COMPANY (US) 2010-11-11 — — WO disclosed
US-20100286209-A1 VINYL INDAZOLYL COMPOUNDS ELI LILLY AND COMPANY 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250248998-A1 LRRK2 Inhibitors LRRK2, PARK7, PINK1 CYP4F2 4693/4885CYP4A11 4756/4885CA12 4880/4885
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors LRRK2, SNCA, ROS1 CYP4F2 4675/4885CYP4A11 4178/4885CA12 4863/4885
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, PARK7, PINK1 CYP4F2 4254/4885CYP4A11 4691/4885CA12 4879/4885
US-20120083511-A1 CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL ADH1A, ADH1C, ADH5 CYP4F2 2607/4885CYP4A11 2403/4885CA12 1317/4885
US-12441707-B2 Indazole compounds BRCA1, IDH2, TP53 CYP4F2 1244/4885CYP4A11 275/4885CA12 3088/4885
US-20100286209-A1 VINYL INDAZOLYL COMPOUNDS VHL, IDH3B, IDH3A CYP4F2 1437/4885CYP4A11 591/4885CA12 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.